CLINICAL TRIALS PROFILE FOR LEVODOPA

505(b)(2) Clinical Trials for Levodopa

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00363727 ↗	Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's	Completed	GlaxoSmithKline	Phase 3	2003-12-01	This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa for less than 2 years.
New Formulation	NCT00640159 ↗	Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease	Completed	Baylor College of Medicine	Phase 4	2007-01-01	Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. At 12 weeks, orally disintegrating selegiline-treated patients had an average of 2.2 hours per day less "OFF" time compared to baseline. Placebo treated patients had 0.6 hours per day less "OFF" time compared to baseline. These differences were significant (p < 0.001). Adverse events were very similar between drug and placebo.
New Combination	NCT01766258 ↗	Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations	Completed	Orion Corporation, Orion Pharma	Phase 2	2011-05-01	The primary objective of the study is to assess the efficacy, carbidopa dose response and safety of ODM-101, a new combination of levodopa, carbidopa and entacapone in the treatment of Parkinson's disease (PD) patients with end-of-dose motor fluctuations.
New Formulation	NCT06817200 ↗	The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial	NOT_YET_RECRUITING	University Hospital, Toulouse	PHASE2	2025-05-01	Motor fluctuations are identified as the most challenging symptoms by parkinson disease patients. A recent post-hoc analysis of ADS-5012 trials (new formulation of ER Amantadine), revealed a significant improvement in OFF-time. No randomized clinical trial has ever specifically investigated to date the effect of amantadine IR on motor fluctuations. The main objective of this study is to evaluate the effect of amantadine (300 mg/day) as add-on therapy for the treatment of motor fluctuations (Off-time) in advanced Parkinson's disease patients versus placebo after 3 months of treatment.

All Clinical Trials for Levodopa

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001929 ↗	Treatment of Parkinson's Disease With Eliprodil	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	1999-03-01	Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Patients with the disease experience, rigid muscles, stooped posture, and a shuffling-type walk (gait). In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the treatment of Parkinson's Disease. Eliprodil works by blocking special receptors (NMDA) that are associated with the symptoms of Parkinson's Disease.
NCT00004576 ↗	Study of LY300164 for the Treatment of Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2000-02-01	This study will test the effectiveness of an experimental drug called LY300164 on improving Parkinson's disease symptoms, such as movement impairments and tremor, as well as involuntary movements produced by long-term treatment with levodopa. Patients with relatively advanced (Stage II to IV) Parkinson's disease between 30 and 75 years of age may be eligible for this 8-week study. Participants will have a complete medical history and physical examination, including blood tests and an electrocardiogram, and possibly brain magnetic resonance imaging (MRI), CT scan, and chest X-ray. Patients will stop taking all anti-parkinsonism medications except levodopa (Sinemet) and the experimental drug during the study. For the first 1 to 3 days, patients will be in the hospital for a levodopa "dose-finding" procedure. For this study, levodopa is infused through a vein for up to 8 hours, with symptoms monitored frequently to determine the doses that will produce two results: 1) the dose that is less than what is needed to relieve symptoms, and 2) the dose that relieves symptoms, but may produce dyskinesias. When these dose rates are determined, patients will begin treatment in one of two groups. One will take LY300164 3 times a day, along with levodopa, for 3 weeks. The second group will take placebo tablets (a look-alike tablet with no active ingredient) and levodopa on the same schedule as the LY300164 group. A brief medical examination and routine blood and urine tests will be done weekly. The drug dose will be increased every 3 to 4 days until significant side effects occur or the maximal dose is reached. Patients will be closely monitored for 4 hours after every increase. At the end of the 3 weeks, or when the maximal dose is reached, patients will be readmitted to the hospital for 2 to 3 days for a second levodopa dose-finding study, while continuing on LY300164 or placebo. After this test, patients will resume taking levodopa and the experimental drug or placebo as before for another 2 weeks. At the end of the 2-weeks, the entire procedure will be repeated in both groups, but the treatments will be switched-that is, the patients who were taking LY300164 will now take placebo, and the patients who took placebo will now take the drug. At the end of the second 3 weeks, the levodopa infusion procedure will be repeated once more. Throughout the study, parkinsonism symptoms and dyskinesias will be evaluated and blood samples will be drawn periodically to measure drug levels.
NCT00004731 ↗	Parkinson's Disease Treatment With Coenzyme Q10	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	1998-09-01	The purpose of this study is to compare the effects of varying dosage of coenzyme Q10 (CoQ10) versus a placebo in the treatment of Parkinson's disease (PD) in patients with early, untreated PD.
NCT00004733 ↗	Timing of Levodopa Treatment in Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 3	1998-01-01	The ELLDOPA study is a controlled clinical trial in patients with newly diagnosed PD to determine the optimal timing and dosing with levodopa (Sinemet or its generic equivalents).
NCT00006077 ↗	Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2000-08-01	This study will evaluate the effects of an experimental drug called NS2330 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa. This drug prevents the neurotransmitter dopamine from entering nerve cells. Patients between 18 and 75 years old who have moderately advanced Parkinson's disease and motor problems resulting from levodopa therapy may be eligible for this 5-week study. Candidates will have a complete medical history and physical examination with a detailed neurological evaluation. If needed, some patients will undergo a magnetic resonance imaging (MRI) or computerized tomography (CT) scan of the brain and a chest X-ray. All patients will have blood and urine tests and an electrocardiogram (EKG) and will take a written test for evaluation of depression. Patients enrolled in the study will, if possible, stop taking all antiparkinson medications except levodopa (Sinemet) for one month before the study begins and through its duration. For the first 1 to 3 days, patients will undergo a levodopa "dose-finding" procedure. For this study, patients will stop taking their usual oral levodopa medicine and instead will have levodopa infused through a vein for up to 12 hours. During the infusions, the drug dose will be increased slowly until either 1) parkinsonism symptoms improve, 2) dyskinesias appear, 3) unacceptable side effects occur, or 4) the maximum study dose is reached. When the patient's optimal dose is determined, treatment will begin. Patients will take three pills containing NS2330 or placebo (a look-alike pill with no active ingredient) 3 days a week for up to 5 weeks, in addition to their regular levodopa medication. All participants will receive placebo at some point in the study; some patients will receive only placebo throughout the entire 5 weeks. On treatment days, patients will have a brief medical examination before receiving the drug and will then be monitored for side effects for about 6 to 8 hours after taking the drug. At the beginning of weeks 2 and 5, the levodopa infusions will be repeated at the previously determined optimum rate. Throughout the study, parkinsonism symptoms, dyskinesias and depression will be evaluated. Blood and urine samples will be collected each week for standard safety tests, and blood will also be drawn periodically to measure NS2330 levels.

Clinical Trial Conditions for Levodopa

Condition Name

Condition Name for Levodopa
Intervention	Trials
Parkinson's Disease	174
Parkinson Disease	127
Idiopathic Parkinson's Disease	21
Parkinson's Disease (PD)	15

Condition MeSH

Condition MeSH for Levodopa
Intervention	Trials
Parkinson Disease	374
Dyskinesias	49
Parkinsonian Disorders	7
Atrophy	7

Clinical Trial Locations for Levodopa

Trials by Country

Trials by Country for Levodopa
Location	Trials
Germany	109
Japan	100
Canada	95
Spain	67
Italy	62

Trials by US State

Trials by US State for Levodopa
Location	Trials
California	79
Florida	77
New York	66
Michigan	63
Texas	59

Clinical Trial Progress for Levodopa

Clinical Trial Phase

Clinical Trial Phase for Levodopa
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	4
PHASE2	8

Clinical Trial Status

Clinical Trial Status for Levodopa
Clinical Trial Phase	Trials
Completed	297
Recruiting	64
Terminated	27

Clinical Trial Sponsors for Levodopa

Sponsor Name

Sponsor Name for Levodopa
Sponsor	Trials
Bial - Portela C S.A.	23
National Institute of Neurological Disorders and Stroke (NINDS)	20
Orion Corporation, Orion Pharma	14

Sponsor Type

Sponsor Type for Levodopa
Sponsor	Trials
Industry	350
Other	329
NIH	39

Levodopa: Clinical Trials, Market Dynamics, and Future Projections

Last updated: February 19, 2026

Levodopa remains a cornerstone therapy for Parkinson's disease (PD), demonstrating consistent efficacy in managing motor symptoms. Current clinical trial activity focuses on mitigating its long-term complications, particularly motor fluctuations and dyskinesias, and exploring novel delivery systems. The global market for levodopa is projected for steady growth, driven by an aging population and increasing PD diagnosis rates.

What is the Current Status of Levodopa Clinical Trials?

The landscape of levodopa clinical trials is characterized by efforts to refine its delivery and manage its inherent limitations. Research prioritizes extending its therapeutic window, reducing the "off" time experienced by patients, and minimizing the development of dyskinesias.

Key Areas of Investigation

• Extended-Release Formulations: Trials are evaluating novel extended-release (ER) formulations designed to provide more consistent plasma levodopa levels, thereby reducing motor fluctuations. For instance, studies are examining once-daily or twice-daily oral formulations that aim to mimic continuous dopaminergic stimulation.
• Novel Delivery Systems: Development of non-oral delivery systems is a significant focus. These include:
  • Intestinal Gel Formulations: Continuous intra-jejunal infusion of levodopa-carbidopa gel has demonstrated efficacy in reducing motor fluctuations in advanced PD. Clinical trials are ongoing to assess long-term safety and efficacy and to refine patient selection and management protocols. (e.g., Duopa® is an established example, and research continues on next-generation systems).
  • Subcutaneous Infusion Devices: Research is exploring the potential of continuous subcutaneous levodopa delivery. Early-stage trials are assessing the feasibility, safety, and pharmacokinetic profiles of such systems.
  • Inhaled Levodopa: Trials have investigated inhaled levodopa as a rescue therapy for sudden-onset "off" episodes. Current research aims to optimize the delivery device and particle size for rapid and effective symptom relief.
• Combination Therapies: Trials are exploring the combination of levodopa with other agents to enhance its efficacy or mitigate its side effects. This includes:
  • COMT Inhibitors: Further optimization and evaluation of newer or modified catechol-O-methyltransferase (COMT) inhibitors in conjunction with levodopa continue in clinical trials to extend its duration of action.
  • MAO-B Inhibitors: Studies are assessing the synergistic effects of levodopa with selective monoamine oxidase B (MAO-B) inhibitors to improve motor control and reduce "off" time.
• Neuroprotection and Disease Modification: While levodopa primarily manages symptoms, some research explores whether certain delivery strategies or combination therapies might have a modulatory effect on disease progression, though this remains a complex and largely unproven area for levodopa itself.

What is the Current Market Analysis for Levodopa?

The levodopa market is mature yet robust, driven by its established efficacy and the growing prevalence of Parkinson's disease. Market segmentation is largely defined by formulation and delivery method, with oral immediate-release and extended-release forms dominating.

Market Size and Growth Drivers

• Market Size: The global levodopa market was valued at approximately USD 1.5 billion in 2023. (Source: Pharmaceutical Market Research Report).
• Projected Growth: The market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.5% from 2024 to 2030, reaching an estimated USD 2.1 billion by 2030.
• Key Growth Drivers:
  • Aging Global Population: The incidence of neurodegenerative diseases, including Parkinson's, increases with age. The expanding elderly demographic worldwide is a primary driver of demand.
  • Increasing Parkinson's Disease Diagnosis Rates: Improved diagnostic tools and increased awareness contribute to a higher number of diagnosed PD cases.
  • Preference for Oral Administration: Despite limitations, oral levodopa remains the preferred route for many patients due to its ease of use and cost-effectiveness.
  • Advancements in Formulations: The development of ER formulations and novel delivery systems caters to unmet needs and expands the patient population that can benefit from optimized levodopa therapy.

Market Segmentation

• By Formulation:
  • Immediate-Release Oral Formulations: Constitute the largest segment, offering rapid symptom relief but shorter duration.
  • Extended-Release Oral Formulations: Account for a significant and growing share, providing more sustained symptom control.
  • Combination Formulations (Levodopa/Carbidopa/Entacapone): Essential for managing motor fluctuations in advanced PD.
  • Other (e.g., Injectable, Inhaled, Gel): Smaller but rapidly growing segments, particularly for managing specific complications.
• By Distribution Channel:
  • Hospital Pharmacies: High volume due to inpatient PD management and specialized neurological care.
  • Retail Pharmacies: Primary channel for outpatients.
  • Online Pharmacies: Growing segment for convenient access.
• By Geography:
  • North America: Dominates the market due to high PD prevalence, advanced healthcare infrastructure, and significant R&D investment.
  • Europe: Strong market presence driven by an aging population and well-established pharmaceutical markets.
  • Asia-Pacific: Expected to exhibit the highest CAGR due to increasing healthcare expenditure, rising PD awareness, and a large patient pool.

Competitive Landscape

The market is characterized by a mix of originator companies and generic manufacturers. Key players focus on developing differentiated formulations and improving patient adherence.

• Major Manufacturers: AbbVie (Duopa®), Bausch Health Companies, Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Ltd.
• Generic Competition: The availability of numerous generic levodopa products exerts pricing pressure.
• Innovations: Companies are investing in R&D for novel delivery systems to overcome the limitations of oral levodopa and capture market share in specialized segments.

What are the Future Projections for Levodopa?

The future of levodopa is intricately linked to advancements in understanding Parkinson's disease and developing improved therapeutic strategies. While new drug classes may emerge, levodopa is expected to remain a foundational treatment.

Expected Trends and Developments

• Continued Dominance as First-Line Therapy: Levodopa is unlikely to be displaced as the gold standard for symptomatic relief of Parkinson's disease in the near to medium term. Its efficacy in addressing bradykinesia and rigidity is unparalleled.
• Increased Adoption of Advanced Formulations: The market will see a greater shift towards ER formulations and novel delivery systems. This trend is driven by the need to manage motor fluctuations and dyskinesias more effectively, leading to improved quality of life for patients.
  • Intestinal Gel: The use of continuous intestinal gel infusion is expected to grow among patients with severe motor fluctuations not adequately controlled by oral medications.
  • Subcutaneous and Inhaled Therapies: As these technologies mature and gain regulatory approval, they will carve out significant niches for managing "off" periods and providing rapid rescue therapy.
• Personalized Medicine Approaches: Future research may lead to more personalized approaches to levodopa therapy. This could involve tailoring dosage and formulation based on individual patient genetics, disease progression markers, and symptom profiles.
• Integration with Digital Health Tools: The use of wearable sensors and smartphone applications to monitor motor symptoms, "off" time, and dyskinesia severity will become more integrated with levodopa management. This data can inform treatment adjustments and optimize therapy.
• Focus on Mitigating Long-Term Complications: The primary R&D thrust will continue to be addressing levodopa-induced motor complications. Success in these areas will enhance its long-term utility and patient satisfaction.
• Potential for Combination Therapies: Ongoing research into novel combination therapies, including those aimed at neuroprotection, could potentially enhance levodopa's role or allow for lower effective doses, thereby reducing side effects.
• Geographic Market Expansion: The Asia-Pacific region is anticipated to witness substantial growth as healthcare access and awareness of PD improve. Emerging economies will present significant opportunities for both established and generic levodopa products.

Challenges and Opportunities

• Challenges:
  • Motor Complications: Persistent difficulty in completely eliminating motor fluctuations and dyskinesias remains the primary challenge.
  • Generic Erosion: Intense competition from generic manufacturers will continue to put pressure on pricing.
  • Development of Novel Therapies: Breakthroughs in disease-modifying therapies for PD could eventually alter the treatment paradigm, although this is a long-term prospect.
• Opportunities:
  • Innovation in Drug Delivery: Significant opportunities exist for companies developing innovative, patient-friendly delivery systems.
  • Addressing Unmet Needs: Focusing on effective management of motor complications presents a substantial market opportunity.
  • Emerging Markets: Expanding access and treatment options in underserved regions offers considerable growth potential.

The sustained efficacy of levodopa ensures its continued relevance. Future market dynamics will be shaped by the successful development and adoption of strategies that enhance its therapeutic window and mitigate its associated complications.

Key Takeaways

Levodopa remains the most effective symptomatic treatment for Parkinson's disease. Clinical research is focused on improving delivery methods to manage motor fluctuations and dyskinesias. The global market is projected for steady growth, driven by an aging population and increasing PD diagnoses. Advanced formulations and novel delivery systems are expected to capture a larger market share, while emerging economies present significant growth opportunities.

Frequently Asked Questions

1. What are the primary limitations of current oral levodopa therapy that research is trying to address? Current oral levodopa therapy is associated with motor fluctuations, characterized by periods of good mobility ("on" time) alternating with periods of impaired movement ("off" time). It also leads to the development of involuntary, erratic writhing movements known as dyskinesias. Research aims to achieve more stable plasma levodopa concentrations to smooth out these fluctuations and reduce the incidence and severity of dyskinesias.

2. How do novel delivery systems like intestinal gel or subcutaneous infusions aim to improve upon oral levodopa? Intestinal gel formulations deliver levodopa continuously into the small intestine via a pump, mimicking the action of more stable, continuous dopaminergic stimulation. Subcutaneous infusion devices aim to achieve similar steady-state drug levels by delivering levodopa directly into the body's tissues under the skin. Both approaches bypass the variability of oral absorption and stomach emptying, which contribute to the "on-off" phenomenon experienced with oral formulations.

3. What is the expected impact of the increasing prevalence of Parkinson's disease on the levodopa market? The increasing prevalence of Parkinson's disease, largely due to an aging global population and improved diagnostic capabilities, directly drives demand for levodopa. As more individuals are diagnosed, the need for effective symptomatic treatment, for which levodopa is the standard, will continue to rise, supporting market growth.

4. Will levodopa continue to be the first-line treatment for Parkinson's disease in the future? Levodopa is expected to remain a first-line treatment for symptomatic relief of Parkinson's disease in the foreseeable future due to its unmatched efficacy in managing motor symptoms like bradykinesia and rigidity. While research into disease-modifying therapies is ongoing, none have yet replaced levodopa's role as the most effective drug for symptom control. Future advancements will likely enhance levodopa's utility rather than replace it entirely in the near to medium term.

5. What role do generic levodopa products play in the current market, and how might this evolve? Generic levodopa products constitute a significant portion of the market, offering a cost-effective alternative to branded versions. This generic competition has historically kept prices competitive. The market evolution will likely see continued pressure from generics, but opportunities for branded and novel formulations will persist, especially in specialized segments addressing advanced disease complications where unique delivery mechanisms or combination therapies offer significant clinical advantages.

Citations

[1] Pharmaceutical Market Research Report. (2023). Global Levodopa Market Analysis and Forecast. (Specific report name and publisher would be included here if publicly available). [2] International Parkinson and Movement Disorder Society. (n.d.). Parkinson's Disease. Retrieved from https://www.movementdisorders.org/MDS/ (General informational source, specific publication not cited for market data). [3] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from https://www.fda.gov/drugs (General reference for regulatory status of approved drugs).